Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
I-020502 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| I-020502 | DRUG | 1 mcg/mL TG-PDGF.AB |
Inclusion Criteria: 1. Written informed consent by the patient or his/her legal representative. 2. Male or female, aged ≥ 18 years. 3. Female with childbearing potential with a negative pregnancy test within 3 day prior to surgery (screening). 4. Patients with burn wound(s) between ≥ 5 % and ≤ 50 %...
I-020502 is an investigational small molecule being studied for use in burns. It is being evaluated as a treatment to support meshed skin autografting in patients with burn injuries. The drug is in Phase 2 clinical development and has not been approved by regulatory authorities.
I-020502 is being developed by Baxter International Inc., a company publicly traded under the ticker symbol BAX. The drug is currently in Phase 2 clinical development for the treatment of burns.
I-020502 is in Phase 2 clinical development. It is an investigational drug and has not been approved for commercial use. A Phase 2 clinical trial of the drug has been completed, and it remains under investigation for the treatment of burns.
I-020502 has been studied in one completed Phase 2 clinical trial with the identifier NCT00471939. The trial, titled "Safety and Efficacy of I-020502 in Meshed Skin Autografting," enrolled 10 participants with burns in Germany. The study was open-label and uncontrolled.
I-020502 is the primary name used for this investigational drug in clinical development. No alternative names have been reported for this compound in the available clinical trial information.